



Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced Non-Small Cell Lung Cancer

October 5, 2020

Durable Anticancer Activity Observed in Patients Whose Cancer Had Progressed Despite Prior Treatment With Chemotherapy and/or Immunotherapy

Safety and Tolerability Similar to Previously Reported Phase 1 Results in Patients with Non-Small Cell Lung Cancer

THOUSAND OAKS, Calif., Oct. 5, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive topline Phase 2 results from the CodeBreak 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 126 patients with *KRAS G12C*-mutant advanced non-small cell lung cancer (NSCLC), who had failed a median of two prior lines of anti-cancer therapies (immunotherapy and/or chemotherapy).

Sotorasib demonstrated an objective response rate (primary end point) consistent with previously reported Phase 1 data in patients with advanced NSCLC taking the 960 mg daily dose. Other measures of efficacy, including duration of response, were promising and more than half of the responders were still on treatment and continuing to respond as of the data cutoff date. Safety and tolerability were similar to previously reported data in Phase 1 in patients with advanced NSCLC.

"Targeting *KRAS* has been a 40-year quest that has left patients with limited options. These topline data underscore our belief in the potential for sotorasib to become the standard of care for non-small cell lung cancer patients with the *KRAS G12C* mutation who remain in need of new treatment options," said David M. Reese, M.D., executive vice president of Research and Development at Amgen. "We now have more than 500 patients who have been enrolled across clinical studies, and we are rapidly moving forward with a broad-based development program, which includes monotherapy studies in non-small cell lung cancer, colorectal cancer and other solid tumors harboring the *KRAS G12C* mutation, as well as a suite of combination studies. We look forward to discussing the current results with the U.S. Food and Drug Administration (FDA) and other regulatory agencies, to determine the best path forward for sotorasib as a potential treatment for patients with NSCLC harboring the *KRAS G12C* mutation."

Detailed results of this potentially registrational Phase 2 clinical study in patients with advanced NSCLC will be submitted to the IASLC 2020 World Congress on Lung Cancer taking place January 2021. A global Phase 3 randomized active-controlled confirmatory study comparing sotorasib to docetaxel in *KRAS G12C*-mutant NSCLC patients (CodeBreak 200) has begun recruiting.

About *KRAS*

The *RAS* gene family, which has been the subject of almost four decades of research, contains some of the most frequently mutated oncogenes in human cancers.^{1,2} Targeting the *KRAS* protein, the most commonly altered family member in solid tumors, has been one of the toughest challenges in cancer research.¹ A specific mutation known as *KRAS G12C*, is a major driver of tumor growth, occurring broadly across solid tumor indications. In the U.S., about 13% of patients with non-small cell lung cancer harbor the *KRAS G12C* mutation.^{3,4} It is also found in approximately 3-5% of colorectal cancers and 1-2% of numerous other solid tumors, making this among the most broadly represented mutations across cancer patient subgroups.^{5,6,7,8,9} With the discovery of a unique surface groove in the *KRAS*^{G12C} protein, Amgen developed and advanced the first investigational *KRAS*^{G12C} inhibitor into the clinic and is exploring the potential of *KRAS*^{G12C} inhibition across multiple tumor types for patients who remain in dire need of treatment options.^{1,10}

About CodeBreak

The CodeBreak clinical development program for Amgen's investigational drug sotorasib is designed to treat patients with an advanced solid tumor with the *KRAS G12C* mutation and address the longstanding unmet medical need for these cancers. As the most advanced *KRAS G12C* clinical development program, CodeBreak has enrolled more than 500 patients across 13 tumor types since its inception.

CodeBreak 100, the Phase 1 and 2, first-in-human, open-label multicenter study, enrolled patients with *KRAS G12C*-mutant solid tumors. Eligible patients must have received a prior line of systemic anticancer therapy, consistent with their tumor type and stage of disease. The primary endpoint for the Phase 2 study was centrally assessed objective response rate. The study enrolled 126 patients, 123 of whom had centrally evaluable lesions by RECIST at baseline.

Amgen's single-arm Phase 2 trial in colorectal cancer (CRC) (also part of CodeBreak 100) is fully enrolled and topline results are expected in 2021. A global Phase 3 randomized active-controlled confirmatory study comparing sotorasib to docetaxel in *KRAS G12C*-mutant NSCLC patients (CodeBreak 200) has begun recruiting. Amgen is also enrolling several Phase 1b combination studies across various advanced solid tumors (CodeBreak 101).

About Amgen Oncology

Amgen Oncology is searching for and finding answers to incredibly complex questions that will advance care and improve lives for cancer patients and their families. Our research drives us to understand the disease in the context of the patient's life – not just their cancer journey – so they can take control of their lives.

For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them.

At Amgen, we are driven by our commitment to transform the lives of cancer patients and keep them at the center of everything we do.

To learn more about Amgen's innovative pipeline with diverse modalities and genetically validated targets, please visit [AmgenOncology.com](https://www.amgenoncology.com). For more information, follow us on www.twitter.com/amgenoncology.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company, including BeiGene, Ltd. or any collaboration or potential collaboration in pursuit of therapeutic antibodies against COVID-19 (including statements regarding such collaboration's, or our own, ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 or antibodies against targets other than the SARS-CoV-2 receptor binding domain, and/or to produce any such antibodies to potentially prevent or treat COVID-19), or the Otezla[®] (apremilast) acquisition (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, outcomes, progress, or effects relating to studies of Otezla as a potential treatment for COVID-19, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

CONTACT: Amgen, Thousand Oaks

Trish Rowland, 805-447-5631 (media)
Megan Fox, 805-447-1423 (media)
Arvind Sood, 805-447-1060 (investors)

References

- ¹ Cox AD, et al. Nat Rev Drug Discov. 2014;13:828-851.
- ² Fernandez-Medarde A, et al. Genes Cancer. 2011;2:344-358.
- ³ Biernacka A, et al. Cancer Genet. 2016;209:195-198.
- ⁴ Stephen AG, et al. Cancer Cell. 2014;25:272-281.
- ⁵ Neumann J, et al. Pathol Res Pract. 2009;205:858-862.
- ⁶ Jones RP, et al. Br J Cancer. 2017;116:923-929.
- ⁷ Wiesweg M, et al. Oncogene. 2019;38:2953-2966.
- ⁸ Canon J, et al. Nature. 2019;575:217-223.
- ⁹ Zhou L, et al. Med Oncol. 2016;33:32.
- ¹⁰ Ryan MB, et al. Nat Rev Clin Oncol. 2018;15:709-720.



 View original content to download multimedia:<http://www.prnewswire.com/news-releases/amgen-announces-positive-topline-phase-2-results-for-investigational-kras-g12c-inhibitor-sotorasib-in-advanced-non-small-cell-lung-cancer-301145947.html>

SOURCE Amgen